The obtained results were therefore in conflict with previously published research [12] that analyzed DDX39A protein levels in 2 reference NBL cell lines and primary tumor samples before and after treatment with 10 μM ATRA and observed higher DDX39A expression in undifferentiated cells. The gene discussed is DDX39A; the disease is neoplasm.